News
AstraZeneca, Daiichi Sankyo enter collaboration for novel HER2-targeting antibody-drug conjugate
Trastuzumab deruxtecan is currently in development for the treatment of multipleHER2-expressing cancers, including breast and gastric cancer, and in patients withHER2-low expression.
Novartis acquires full rights to IFM Tre's portfolio of NLRP3 inhibitors
Preclinical studies have shown that IFM Tre's molecules can selectively suppress inflammation caused by the NLRP3 inflammasome while allowing the rest of the immune system to continue normal operations.
Israel's Ocular discovery partners with all India Institute of Medical Sciences
Ocular Discovery and AIIMSsigned a novel research partnership investigating the mechanism of action of Dipyridamole, for optimized delivery and therapeutic treatment of various Ocular Surface Disorders.
AstraZeneca spearheads development of a new International Life Science Innovation Park in China
The International Life Science Innovation Park will be built by the Wuxi municipal government and Wuxi High-tech District and supported by AstraZeneca as a founding partner
voice for BT and BEST 2026
